Solid Tumor Clinical Trials

104 studies are recruiting for solid tumor in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. Study of STP938 (Dencatistat) in Advanced Solid Tumours

   The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy. The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Comprehensive Hematology Oncology, LLC, St. Petersburg, Florida

   Locations

   7 in total

   Run by

   Step Pharma, SAS

   See if you can join NCT06297525 on ClinicalTrials.gov

2. FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers

   The purpose of this study is to test the safety of MSK-TCR5 in participants with advance solid tumor cancer that has a KRAS, HRAS, or NRAS G12D mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07638371 on ClinicalTrials.gov

3. MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

   This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of MEM-288 in patients with advanced solid tumors. Eligible sub…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   2 in total

   Run by

   Memgen, Inc.

   See if you can join NCT05076760 on ClinicalTrials.gov

4. An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

   The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of California LA, Los Angeles, California

   Locations

   15 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06401356 on ClinicalTrials.gov

5. Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

   The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Start Lacn, Los Angeles, California

   Locations

   3 in total

   Run by

   Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

   See if you can join NCT07517198 on ClinicalTrials.gov

6. Ex Vivo Expansion (ACT-X)

   The purpose of this study is to understand how the body's immune cells respond to a new type of vaccine (neoantigen vaccine) designed to help the immune system recognize and fight cancer. To do this, the study team will collect a research specimen from participants to study their immune cells' reac…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mayo Clinic in Florida, Jacksonville, Florida

   Run by

   Mayo Clinic

   See if you can join NCT07137312 on ClinicalTrials.gov

7. PET [89Zr]DFO-starPEG in Solid Tumors

   This is a first-in-human, pilot study of the novel PET-imaging radiotracer [89Zr]DFO-starPEG. The study is designed to obtain preliminary data to support future development of this agent as an imaging surrogate to visualize enhanced permeability and retention (EPR)-mediated tracer uptake before adm…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   Robert Flavell, MD, PhD

   See if you can join NCT06894745 on ClinicalTrials.gov

8. A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

   The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer [OC], endometrial cancer [EC], non-sma…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford Women's Cancer Center, Palo Alto, California

   Locations

   58 in total

   Run by

   Eisai Inc.

   See if you can join NCT04300556 on ClinicalTrials.gov

9. Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy

   The investigators will conduct a pilot feasibility and efficacy trial of a newly developed family health communication tool (called Let's Get REAL) in increasing youth involvement in real-time stem cell transplant and cellular therapy decisions (SCTCT). The investigators will pilot the intervention…

   Stage

   Not phased

   Ages

   8 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT06689800 on ClinicalTrials.gov

10. Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

    This is a study that will enroll patients with cancer who have tumors that may have spread. The patients will know what medication they are being given. There will be 2 parts to the study. For the first part of the study only one medication will be taken, and the dose changed to a higher dose over …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas Health Science Center at San Antonio, San Antonio, Texas

    Run by

    Lei Zheng

    See if you can join NCT07086768 on ClinicalTrials.gov

11. VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

    This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.

    Stage

    Phase 1

    Ages

    0 to 30

    Site

    Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

    Locations

    7 in total

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT04796012 on ClinicalTrials.gov

12. 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

    This is a Phase I study to determine the optimal biological dose (OBD) of 5-Azacitidine in combination with PD-1/PD-L1 inhibitors in patients with tumors refractory to PD-1/PD-L1 inhibitors, for which such treatments have been approved.

    Stage

    Phase 1

    Ages

    18 to 99

    Site

    University of Iowa Health Care, Iowa City, Iowa

    Run by

    Mohammed Milhem

    See if you can join NCT07404332 on ClinicalTrials.gov

13. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

    Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCLA Santa Monica Hematology Oncology, Santa Monica, California

    Locations

    20 in total

    Run by

    Astellas Pharma Inc

    See if you can join NCT07094204 on ClinicalTrials.gov

14. Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

    The goal of this clinical trial is to learn if givastomig in combination with standard therapy works to treat adults with cancer in the stomach and/or esophagus (GEA adenocarcinoma). It will also help the researchers to learn more about the safety of givastomig. The main questions it aims to answer…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    I-Mab Site 1016, Goodyear, Arizona

    Locations

    6 in total

    Run by

    I-Mab Biopharma US Limited

    See if you can join NCT07432295 on ClinicalTrials.gov

15. Brodalumab in the Treatment of Immune-Related Adverse Events

    The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Columbia University Irving Medical Center, New York, New York

    Run by

    Brian Henick, MD

    See if you can join NCT06673329 on ClinicalTrials.gov

16. A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

    The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the acti…

    Stage

    Phase 2

    Ages

    1 and older

    Site

    Children's Hospital of Los Angeles (Data Collection Only), Los Angeles, California

    Locations

    16 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05985161 on ClinicalTrials.gov

17. Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors

    The purpose of the study is to find out the usefulness and safety of a dye called Indocyanine Green (ICG for short). This dye will be used to help the surgeon find lymph nodes draining solid tumors inside the abdomen that need to be removed. This may also help the surgeon to find if the cancer has …

    Stage

    EARLY_Phase 1

    Ages

    Up to 20

    Site

    Lurie Children's Hospital, Chicago, Illinois

    Locations

    3 in total

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT05645523 on ClinicalTrials.gov

18. A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

    The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Adventist Health Glendale, Glendale, California

    Locations

    19 in total

    Run by

    Teligene US

    See if you can join NCT06010342 on ClinicalTrials.gov

19. Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies

    This will be a phase 1, open-label, dose-escalation and expansion, FIH trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of JBZ-001, a DHODH inhibitor, in patients with refractory solid and hematological malignancies. The study design includes two independent parts: dose …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Ohio State University, Columbus, Ohio

    Locations

    2 in total

    Run by

    Jabez Bioscience, Inc

    See if you can join NCT06801002 on ClinicalTrials.gov

20. GTB-5550 in Advanced Solid Tumors

    This is a first-in-human Phase 1a/1b trial of a B7-H3-targeted natural killer (NK) cell engager, referred to as a TriSpecific Killer Engager (TriKE), for the treatment of select solid tumor cancers. To be considered for the study, a patient must be 18 years or older, have histologically or cytologi…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT07541573 on ClinicalTrials.gov

21. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Arkansas Medical School, Little Rock, Arkansas

    Locations

    19 in total

    Run by

    NiKang Therapeutics, Inc.

    See if you can join NCT06586957 on ClinicalTrials.gov

22. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

    This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic Scottsdale, Scottsdale, Arizona

    Locations

    15 in total

    Run by

    Tango Therapeutics, Inc.

    See if you can join NCT06810544 on ClinicalTrials.gov

23. A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

    This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Site 0264, Aurora, Colorado

    Locations

    24 in total

    Run by

    K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

    See if you can join NCT04516447 on ClinicalTrials.gov

24. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

    Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Florida Cancer Specialists, Orlando, Florida

    Locations

    18 in total

    Run by

    Incyclix Bio

    See if you can join NCT05735080 on ClinicalTrials.gov

25. A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

    This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Site-113, Duarte, California

    Locations

    17 in total

    Run by

    Biohaven Therapeutics Ltd.

    See if you can join NCT06384807 on ClinicalTrials.gov